The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
HPV‐mediated cervical carcinogenesis: concepts and clinical implications
Open accessAbstract
Persistent infection with a high‐risk human papillomavirus (hrHPV) is generally accepted as a necessary cause of cervical cancer. However, cervical cancer is a rare complication of an hrHPV infection since most such infections are transient, not even giving rise to cervical lesions. On average, it takes 12–15 years before a persistent hrHPV infection may ultimately, via consecutive premalignant stages (ie CIN lesions), lead to an overt cervical carcinoma. This argues that HPV‐induced cervical carcinogenesis is multi‐step in nature. In this review, the data from hrHPV‐mediated in vitro transformation studies and those obtained from analysis of clinical specimens have been merged into a cervical cancer progression model. According to this model, a crucial decision maker in the early stages following infection involves individual susceptibility for certain HPV types depending on the genetic make‐up of immune surveillance determinants. Once a CIN lesion has developed, altered transcriptional regulation of the viral E6/E7 oncogenes, resulting in genomic instability and distinguishing the process of cell transformation from a productive viral infection, probably provides the subsequent important step towards malignancy. The additional (epi)genetic alterations that subsequently accumulate in high‐grade CIN lesions may result in overt malignancy via immortality and growth conditions that gradually become less sensitive to growth‐modulating influences mediated by cytokines and cell–cell and cell–matrix adhesions. The potential implications of hrHPV testing and some other biomarkers deduced from this model for cervical screening and the clinical management of CIN disease are also discussed. Copyright © 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091 · cited 1×
“Telomere erosion is considered to provide an intrinsic division count system that determines the lifespan of normal somatic cells [48].”
BackgroundEpidemiologic classification of human papillomavirus types associated with cervical cancer
Muñoz, N., Bosch, F. X., de Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K. V., Snijders, P. J. F., & Meijer, C. J. L. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021641 · Cited by 6,249
Self-citationPapillomaviruses and cancer: from basic studies to clinical application
zur Hausen, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc798 · Cited by 4,024
The human papilloma virus-16 E7-oncoprotein is able to bind to the retinoblastoma gene product
Dyson, N., Howley, P. M., Münger, K., & Harlow, E. (1989) · Science · doi:10.1126/science.2537532 · Cited by 3,017
Meyerson, M., Counter, C. M., Eaton, E. N., Ellisen, L. W., Steiner, P., Caddle, S. D., Ziaugra, L., Beijersbergen, R. L., Davidoff, M. J., Liu, Q., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80538-3 · Cited by 1,784
Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis
Clifford, G. M., Smith, J. S., Plummer, M., Muñoz, N., & Franceschi, S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600688 · Cited by 1,561
Muñoz, N., Bosch, F. X., Castellsagué, X., Díaz, M., de Sanjose, S., Hammouda, D., Shah, K. V., & Meijer, C. J. L. M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20244 · Cited by 1,104
Self-citationKhan, M. J., Castle, P. E., Lorincz, A. T., Wacholder, S., Sherman, M., Scott, D. R., Rush, B. B., Glass, A. G., & Schiffman, M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji187 · Cited by 1,053
Klaes, R., Friedrich, T., Spitkovsky, D., Ridder, R., Rudy, W., Petry, U., Dallenbach-Hellweg, G., Schmidt, D., & von Knebel Doeberitz, M. (2001) · International Journal of Cancer · doi:10.1002/ijc.1174 · Cited by 1,035
Münger, K., Phelps, W. C., Bubb, V, Howley, P. M., & Schlegel, R. (1989) · Journal of Virology · doi:10.1128/jvi.63.10.4417-4421.1989 · Cited by 1,030
Cited by
Human Papillomavirus Testing in the Prevention of Cervical Cancer
Schiffman, M., Wentzensen, N., Wacholder, S., Kinney, W., Gage, J. C., & Castle, P. E. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq562 · Cited by 759
Meijer, C. J. L. M., Berkhof, J., Castle, P. E., Hesselink, A. T., Franco, E. L., Ronco, G., Arbyn, M., Bosch, F. X., Cuzick, J., Dillner, J., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24010 · Cited by 692
Self-citationNagy, Z., & Tora, L. (2007) · Oncogene · doi:10.1038/sj.onc.1210604 · Cited by 417
New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer
Yamato, K., Yamada, T., Kizaki, M., Ui-Tei, K., Natori, Y., Fujino, M., Nishihara, T., Ikeda, Y., Nasu, Y., Saigo, K., et al. (2008) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701118 · Cited by 110
Interaction between inflammation and angiogenesis during different stages of cervical carcinogenesis
Mazibrada, J., Rittà, M., Mondini, M., De Andrea, M., Azzimonti, B., Borgogna, C., Ciotti, M., Orlando, A., Surico, N., Chiusa, L., et al. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.08.095 · Cited by 94
Wang, Y., Chen, S., Yan, Z., & Pei, M. (2019) · Cell & Bioscience · doi:10.1186/s13578-018-0264-9 · Cited by 56
Low- and high-risk human papillomavirus E7 proteins regulate p130 differently
Barrow-Laing, L., Chen, W., & Roman, A. (2010) · Virology · doi:10.1016/j.virol.2010.01.034 · Cited by 39
De, S. K. (2023) · Medicines for Cancer · doi:10.1016/b978-0-443-13312-1.00009-x · Cited by 1
Metadata
- Authors
- Snijders, P. J., Steenbergen, R. D., Heideman, D. A., & Meijer, C. J.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2005-12-17
- Volume
- 208
- Issue
- 2
- Pages
- 152-164
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2065395166
- Cited by
- 455
- References
- 103
- FWCI
- 14.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
